The aim of the study was to analyze cancer-specific survival in patients who completed a course of radical radiotherapy for prostate adenocarcinoma, taking into account the duration of treatment interruptions as well as factors such as age, Gleason score, and PSA level. The retrospective study included data from 360 patients who underwent radiotherapy at the N.N. Alexandrov National Cancer Centre and the Brest Regional Oncology Dispensary (2008–2016). The median follow-up period was 60 months, and statistical analysis was conducted using Cox regression and Kaplan-Meier methods. The duration of treatment interruptions and the Gleason score had prognostic significance for cancer-specific survival (p < 0.05). Among patients with low and intermediate recurrence risk, interruptions of less than or more than 3 weeks did not affect survival (89,2 % versus 92,5 %, ρlogrank = 0,612). However, in high and very high-risk groups, the study demonstrated a significant impact of radiotherapy interruptions on patient survival (96,1 % versus 89,1 %, ρlogrank = 0,026). The obtained results emphasize the importance of strict adherence to radiation therapy schedules, especially for patients at high risk of disease recurrence. An individualized treatment approach, the use of modern radiation therapy techniques such as IMRT and VMAT, as well as compensation for treatment interruptions, may contribute to improved long-term clinical outcomes.

Introduction . Incidence of brain metastases rises in recent years. Local control after surgical resection of brain metastases is a priority for patients with limited intracranial disease and controlled primary tumor. Surgery should be combined with other methods because of the high risk of local recurrences. Aim . To analyze the overall survival (OS) and influencing factors for patients with brain metastasis after combined therapy. Materials and methods. The retrospective study included 196 patients with stable systemic cancer or available systemic therapy in cases of progressive disease. All patients had from 1 to 3 brain metastasis. Overall survival and influencing factors after surgical and combined therapy were analysed. Results . Median OS for the entire cohort was 16.9 months. The highest levels of OS were achieved for patients with renal cancer (median OS 32.5 months). For patients with non-small cell lung cancer, breast cancer, melanoma and other cancers OS were 18.8; 19.9; 11.0 and 15.3 months, appropriately. Age, continuation of local therapy in brain (surgical intervention, stereotactic radiosurgery), using of the cisplatin for patients with non-small lung cancer brain metastasis were independent factors that have influenced OS. Conclusion . Application of combined therapy for brain metastasis can provide reasonable OS for patients with controlled systemic disease. Using of the cisplatin as a part of combined therapy provide statistically meaningful rise in OS for patients with non-small lung cancer brain metastasis.

Цель. Изучить показатели и факторы прогноза общей выживаемости (ОВ) у пациентов с метастатическим поражением головного мозга после проведения стереотаксической радиохирургии (СРХ) в самостоятельном варианте.Материалы и методы. Проанализированы результаты СРХ 243 пациентов, имеющих от 1 до 10 метастазов в головном мозге диаметром не более 3 см. Все пациенты имели статус по шкале Карновского не менее 70%, не имели экстракраниального прогрессирования, либо имелись резервы системного лечения. Изучены показатели ОВ, определены прогностические факторы после проведения СРХ.Результаты. Медиана ОВ в общей когорте составила 12,2 месяца. Наилучшие показатели ОВ получены у пациентов с метастазами рака почки (медиана ОВ 18,3 месяца) и рака молочной железы (медиана ОВ 16,3 месяца). Медианы ОВ пациентов с меланомой, раком легкого и другими опухолями составили 9,1, 10,4 и 7,6 месяца соответственно. Выявлены статистически значимые различия в показателе ОВ у пациентов с единичным и одиночными метастазами по сравнению с подгруппой пациентов с множественными очагами (медианы ОВ составили соответственно 13,0 месяца, 13,4 месяца, 7,3 месяца). Медиана ОВ при однократном сеансе СРХ составила 9,9 месяца, при 2 сеансах – 19,7 месяца, а при 3 и более сеансах достигнута не была. Независимыми факторами, влиявшими на показатели ОВ, являлись: источник метастазирования, число метастазов и факт проведения повторных сеансов СРХ при интракраниальном прогрессировании.Выводы. Проведение СРХ при метастазах в головном мозге обеспечивает удовлетворительные показатели ОВ у пациентов с хорошим функциональным статусом и контролируемым экстракраниальным процессом. Наилучшие показатели достигаются у пациентов с метастазами рака почки и молочной железы и ограниченным метастатическим поражением. Purpose. To study the indicators and predictors of overall survival (OS) in patients with metastatic brain lesions after performing stereotactic radiosurgery (SRS) as an independent option.Materials and methods. The results of SRS in 243 patients with 1 to 10 metastases in the brain withthe diameter of not more than 3 cm were analyzed. All patients had the Karnofsky status of at least 70%, no extracranial progression, or the reserves of systemic treatment. The OS parameters were studied and the prognostic factors after SRS were determined.Results. The median of OS in the total cohort was 12.2 months. The best OS indicators were obtained in patients with metastases of kidney cancer (median of OS – 18.3 months) and breast cancer (median of OS – 16.3 months). Median of OS in patients with melanoma, lung cancer, and other tumors was 9.1, 10.4, and 7.6 months, respectively. Statistically significant differences of OS were revealed in patients with single and solitary metastases if compared to the subgroup of patients with multiple foci (medians of OS were 13.0 months, 13.4 months, 7.3 months, respectively). The median of OS with a single SRS session was 9.9 months, with 2 sessions – 19.7 months, and with 3 or more sessions, it was not achieved. The independent factors that influenced the OS indicators were the following: the source of metastasis, the number of metastases, and the fact of repeated sessions of SRS with intracranial progression.Conclusion. SRS for brain metastases provides satisfactory OS values in patients with good functional status and controlled extracranial process. The best performance is achieved in patients with metastatic renal and breast cancer and limited metastatic lesion.

Цель. Оценить уровень локального контроля, частоту осложнений и количество энуклеаций после применения брахитерапии и стереотаксической радиохирургии для лечения первичной меланомы хориоидеи. Материалы и методы. Группа проспективного исследования состояла из пациентов, которым в период с 2019 по 2022 г. была выполнена СРХ (52 пациента). Ретроспективную группу составили 57 пациентов с сопоставимыми размерами опухоли, которым в период с 2017 по 2019 г. была выполнена брахитерапия. Конечными точками исследования были локальный контроль и регистрация осложнений. В обеих группах оценивались следующие постлучевые осложнения: оптикоретинопатия, отслойка сетчатки, гемофтальм, вторичная глаукома. Оценка безметастатической выживаемости проводилась путем построения кривых Каплана – Майера. Результаты. Медиана наблюдения в общей когорте составила 32 месяца. Годичная безрецидивная выживаемость в группе СРХ составила 100%, в группе БТ – 79,9±2,8% (р log-rank = 0,001). Годичная инцидентность оптикоретинопатии в группе СРХ составила 19,5±6,7%, в группе БТ – 15,8±4,8% (p log-rank = 0,29). Годичная инцидентность отслойки сетчатки составила 18,2±6,4% в группе СРХ, 3,5±1,0% в группе БТ (p log-rank = 0,017). Годичная инцидентность вторичной глаукомы в группе СРХ составила 13,0±5,5%, в группе БТ – 1,7±1,1% (p log-rank = 0,003). Уровень сохранения глазного яблока в течение года после лечения составил 89,2±5,1% и 86,3±2,1% после СРХ и БТ соответственно (p log-rank = 0,9). Для категории Т2 годичная беспрогрессивная выживаемость в группе СРХ составила 100,0%, в группе БТ – 98,5±0,8% (p log-rank = 0,159). Для категории Т3 годичная беспрогрессивная выживаемость в группе СРХ составила 100,0%, в группе БТ – 96,4±3,5% (p log-rank = 0,19). Заключение. Требуются дальнейшие исследования для определения группы пациентов, которым целесообразно выполнять СРХ в связи с большей, по сравнению с БТ, частотой осложнений. Purpose. To evaluate the level of local control, the rate of complications and the number of enucleations after the brachytherapy and stereotactic radiosurgery for the treatment of primary choroidal melanoma. Materials and methods. The prospective study group consisted of patients who underwent SRS between 2019 and 2022 (52 patients). The retrospective group consisted of 57 patients with comparable tumor sizes who underwent brachytherapy between 2017 and 2019. The endpoints of the study were local control and registration of complications. In both groups, the following post-radiation complications were assessed: optical retinopathy, retinal detachment, hemophthalmos, secondary glaucoma. Metastatic-free survival was assessed by constructing Kaplan-Meier curves. Results. The median follow-up in the total cohort was 32 months. One-year disease-free survival in the SRS group was 100%, in the BT group it was 79.9±2.8% (p log-rank = 0.001). The 1-year incidence of optical retinopathy in the SRS group was 19.5±6.7%, in the BT group it was 15.8±4.8% (p log-rank = 0.29). The 1-year incidence of retinal detachment was 18.2±6.4% in the SRS group, 3.5±1.0% in the BT group (p log-rank = 0.017). The 1-year incidence of secondary glaucoma in the SRS group was 13.0±5.5%, in the BT group it was 1.7±1.1% (p log-rank = 0.003). The level of preservation of the eyeball during the year after treatment was 89.2±5.1% and 86.3±2.1% after SRS and BT, respectively (p log-rank = 0.9). For category T2, one-year progression-free survival in the SRS group was 100.0%, in the BT group it was 98.5±0.8% (p log-rank = 0.159). For category T3, one-year progression-free survival in the SRS group was 100.0%, in the BT group it was 96.4±3.5% (p log-rank = 0.19). Conclusion. Further studies are required to determine the group of patients who should undergo SRS due to the higher complication rate compared to BT.

Treatment of poorly-pigmented tumors of small sizes can be carried out using photodynamic therapy (PDT). The material for the analysis was data on 112 patients. We used data from the Belarusian Cancer Registry, medical records of patients with clinically diagnosed choroid melanoma (C69.3 according to ICD-10) for the period 2013–2021. The size and level of blood flow in the tumors were assessed using an ultrasound machine with a doppler attachment. PDT was carried out using a «UPL PDT» semiconductor laser (Lemt, Republic of Belarus, λ=661 nm) with a light spot diameter of 1 to 3 mm for 60 s per field with a light dose of 50 J/cm2. The entire surface of the tumor was exposed to the action, with the fields “tiled”, from the periphery to the top of the tumor, with overlapping fields. Tumor pigmentation was assessed visually. To evaluate the treatment outcome, the general group of patients was divided into three subgroups according to thickness and basal diameter. Group I – 40 (35.7%) patients, with an average tumor thickness of 1.4±0.2 mm, basal diameter – 5.8±1.5 mm. II – 51 (45.5%) patients, with an average tumor thickness of 2.3 ± 0.3 mm, basal diameter – 7.9 ± 1.5 mm. III – 21 (18.8%) patients. The mean value of the tumor thickness was 3.8±0.4 mm, the basal diameter was 9.8±1.4 mm. After PDT in the general group (n=112), 29 (25.9%) patients had complete tumor resorption, and 83 (74.1%) patients had stabilization. The eyeball was saved in 107 (95.5%) patients. Continued growth and relapse were recorded in 34 patients: 25 (22.3%) and 9 (8.0%), respectively. In 29 (85.3%) patients, the eyeball was preserved after treatment of relapse and continued growth. 5 (4.5%) enucleations were performed. Adjusted one-year cumulative survival was 100%, 3-year and 5-year 95.8±2.4%, 93.7±3.1%, respectively

Цель: Оценить выживаемость пациентов, страдающих почечно-клеточным (ПКР) раком I ст., подвергнутых стереотаксической аблационной лучевой терапии (САЛТ).Материал и методы: В исследование включены 22 пациента, которым в РНПЦ ОМР им. Н. Н. Александрова в период 2018–2022 гг. была проведена САЛТ по поводу впервые выявленной опухоли почки. Общее число облученных опухолей составило 25. Критериями включения в исследования явились: рак почки I стадии, наличие противопоказаний к хирургическому лечению, или отказ от хирургического лечения, а также высокий риск развития послеоперационных осложнений. В исследование включались пациенты с размером образований ≤ 5 см. Лечение осуществлялось на аппарате TrueBeam STx (Varian Medical Systems, США). Предписанная доза составила 48 Гр за 4 фракции, биологически эффективная доза (BED) α / β 3 Гр = 240 Гр, BED α / β 10 Гр = 105 Гр. Конечными точками исследования являлись кумулятивная инцидентность (КИ), скорректированная (СВ) и общая выживаемость (ОВ).Результаты: В 24 случаях при первичном контроле был достигнут локальный контроль заболевания (в 2 в виде полной регрессии, в 15 в виде стабилизации заболевания, в 7 случаях — частичная регрессия опухоли). У 1 пациента был отмечен продолженный рост опухоли и дальнейшее системное прогрессирование заболевания. При оценки локального контроля, медиана наблюдения которого составила 24 месяца, 4-летняя кумулятивная инцидентность составила 4,2 %. Вместе с тем, у 2 пациентов имело место прогрессирования заболевания с развитием отдаленных метастазов, безметастатическая выживаемость составила 86,2 %. За период наблюдения (медиана 24 месяца) умерло 3 человека, все — от причин, не связанных с раком почки. 4-летняя скорректированная выживаемость составила 100 %, общая выживаемость — 85,2 %.Выводы: Полученные предварительные результаты свидетельствуют о том, что стереотаксическая лучевая терапия может быть использована у неоперабельных пациентов, однако необходимо более глубокое изучение отдаленных результатов после проведенного лечения на большей когорте пациентов.

Цель. Определить взаимосвязь дозы облучения с показателями локального контроля и частоты осложнений при проведении предоперационной стереотаксической радиохирургии (пСРХ) у пациентов с крупными церебральными метастазами.Материалы и методы. В исследование включены 54 пациента, которым проведено комбинированное лечение, включающее пСРХ на установке «Гамма-нож» и резекцию метастазов в головном мозге. Был выполнен ROC-анализ для предписанной дозы (ПД), максимального диаметра и объема опухоли. Определена оптимальная точка отсечения для показателя ПД, и в соответствии с этим выделены 2 группы пациентов, в каждую из которых вошло по 27 человек. Изучены показатели кумулятивной инцидентности локальных рецидивов и общей выживаемости (ОВ) для двух групп пациентов.Результаты. Площадь под кривой для параметра ПД составила 0,758 (ДИ 0,577–0,939) с оптимальной точкой отсечения 17 Гр. При использовании ПД более данного значения кумулятивная инцидентность локального рецидива была ниже (log rank p=0,04). Максимальный диаметр и объем опухоли статистически значимого влияния на риск развития локального рецидива не оказали (AUC 0,329 и 0,334 соответственно). В исследуемых группах не зафиксировано случаев радионекроза. Медиана ОВ в группе пациентов с дозами облучения ≤17 Гр и >17 Гр составила 22,4 и 20,7 месяца соответственно (log rank p=1,0).Заключение. Полученные результаты демонстрируют высокую эффективность использования доз >17 Гр при пСРХ в составе комбинированной терапии крупных интракраниальных метастазов, что выражается в повышении локального контроля без увеличения риска осложнений. Purpose. To study the correlation between preoperative stereotactic radiosurgery (pSRS) doses and local recurrences and complication’s rate for large brain metastasis.Materials and methods. We have studied 54 cases of combined therapy for brain metastasis consisted of pSRS on Gamma Knife and surgical resection. Threshold for SRS dose was defined according to ROC-analysis as well as for the largest metastasis diameter and volume. Depending on the SRS dose we divided cases into two groups, each one consisted of 27 patients. The cumulative incidence of the local recurrences and overall survival for the two groups of patients were explored.Results. Area under curve (AUC) for SRS doses was 0.758 (CI 0.577–0.939) with optimal threshold 17 Gy. Cumulative incidence of local recurrence was lower in the case of SRS doses larger than 17 Gy (log rank p=0.04). The largest diameter and tumor volume did not have statistically significant influence on the chance of local recurrence (AUC 0.329 and 0.334 respectively). There were no cases of radionecrosis. Median OS in the groups of patients with SRS doses ≤17 Gy and >17 Gy were 22.4 and 20.7 months, respectively (log rank p=1.0).Conclusion. Received results show high effectiveness of doses >17 Gy for preoperative SRS as part of the combined therapy for large brain metastasis. Such approach can provide improved local control without increase in the complication rate.

The quality of radiation treatment for oncological diseases can be influenced by a large number of factors. Among them, the breaks that occur during the course of radiotherapy play an important role. Split courses of radiotherapy are used in the practice of radiation treatment of head and neck cancer, as well as prostate cancer. Breaks between the stages of the course of radiotherapy lasting 1-2 weeks are carried out in elderly, debilitated patients or in the presence of radiation reactions of 3-4 degrees. Before the start of radiotherapy, a set of measures is taken to prevent radiation reactions. This can affect the fact that the course of radiotherapy will be carried out without interruption. Using Cox regression, it is proposed to evaluate the effect of interruptions in the course of radiotherapy on the outcome of treatment for head and neck tumors, as well as the prostate tumors taking into account the observation period.

The development of radiobiological models made it possible to mathematically describe biological phenomena in the body under the influence of radiation. The history of the development of radiobiological models began immediately after the discovery of X-rays and continues now, overcoming more and more restrictions. The practical application of radiobiological models is an integral part of clinical practice in cancer treatment.

The article provides an overview of the current data on the quality of life in cancer patients, as well as the functional results of radical treatment of prostate cancer. The main goal was to evaluate the functional results in patients after radical prostatectomy, combined radiation therapy, and high dose-rate brachytherapy in 8 to 12 months after treatment. The study included 148 patients treated from 2017 to 2018. The life quality was assessed by specialized questionnaire. The obtained results indicate the better functional results and a higher level of the quality of life of patients after radiation therapy, compared with radical prostatectomy.

The article provides an overview of the current data on the quality of life in cancer patients, as well as the functional results of radical treatment of prostate cancer. The main goal was to evaluate the functional results in patients after radical prostatectomy, combined radiation therapy, and high dose-rate brachytherapy in 8 to 12 months after treatment. The study included 148 patients treated from 2017 to 2018. The life quality was assessed by specialized questionnaire. The obtained results indicate the better functional results and a higher level of the quality of life of patients after radiation therapy, compared with radical prostatectomy.

. Objectives. To conduct a retrospective comparison of long-term oncological outcomes in patients with intermediate-risk prostate cancer after radical prostatectomy, combined radiotherapy and high-dose rate brachytherapy in mono mode. Material and methods. From 2008 to 2011 in the Centre risk prostate cancer patients were radically treated, of which 114 were further followed up after treatment. Patients were divided into 3 groups depending on the type of treatment. Stratification to the intermediate-risk group was performed in accordance with the NCCN criteria. The follow-up period lasted for 8 years. High-dose rate brachytherapy and combined radiotherapy were provided using specialized equipment, radical prostatectomy was performed according to the standard open-access technique. As net results, the event-free survival, cancer specific survival, and overall patients’ survival were evaluated.Results. As a result of the retrospective analysis, the eight-year event-free survival, cancer specific survival turned out to be comparable for all types of treatment. The eight-year overall survival rate made up 90.5%. Conclusions. The studied treatment methods are characterized by good long-term oncological outcomes in patients with intermediate-risk prostate cancer. Taking into account good tolerance and safety of high-dose rate brachytherapy and combined radiotherapy, as well as the oncological results obtained, these methods can be recommended as radical treatment and an alternative to radical prostatectomy in patients suffering from prostate cancer of the intermediate-risk progression group.

Background. Patients suffering from prostate cancer (PCa) with a high risk of progression need the most active treatment tactics. Escalation of radiation dose, larger daily fractions radiation therapy (including high-dose-rate interstitial brachytherapy (HDR-BT)) is a promising approach to the treatment of PCa. Objective of the study . Comparative assessment of the long-term treatment results of patients with PCa with a poor prognosis after external beam radiotherapy (EBRT) and combined radiation therapy, depending on risk factors. Materials and methods . 207patients who received a course EBRT and HDR-BT with EBRT (combined RT) on a radical program for the first detected PCa at the N.N. Alexandrov National Cancer Center of Belarus in 2013—2015 inclusive. All patients were belonged to the group of high and very high risk of progression according to the criteria of the NCCN (National Comprehensive Cancer Network), all were treated with neoadjuvated hormone therapy (medical or surgical castration). The patients were stratified into two groups: HDR-BT with EBRT and EBRT. When conducting combined RT, HDR-brachytherapy was performed in single fraction with a dose of 11.5 Gy, for EBRT it was used as a conventional fractionation (single dose of 2 Gy, total — 44 Gy) and hypofractionation (single dose of 3 Gy, total — 36 Gy). Patient that were not who not included in the combined RT protocol were treated with EBRT under a radical program in a total dose of 78—80 Gy. Results . It was established that in the group of patients after EBRT the median survival was not achieved, the 5-year adjusted survival (AS) was 85.2 + 5.6 %. In the combined RT group, the median survival was also not reached, the 5-year-old AS was 92.2 + 5.9 %. It was found that for the patients with a Gleason score of 7 or more, a significant difference in the AS index was obtained in favor of the HDR-BT with EBRT: the 5-year AS of patients of this subgroup who were exposed to combined RT was 84.6 + 9.8 %, while after EBRT, the 5-year-old AS was 71.0 + 11.2 %. In the subgroup of patients with Gleason sum 7—10, combined RT was associated with statistically significantly better long-term results in compared with EBRT. Conclusion. The application of the method of combined RTfor patients suffering from PCa with a high risk is characterized with satisfactory long-term treatment results.

The article presents the results of a comparative study of the effect of adjuvant radiotherapy on the survival to biochemical recurrence (BCR) in patients undergoing radical prostatectomy (RP) of prostate cancer (PCa) depending on preand post-operative prognosis factors. Adjuvant radiation therapy following prostatectomy in a total focal dose of 60 Gy in patients with locally advanced prostate cancer (pT3a-b) or the localized process with positive surgical margins (rT2R1) and highly differentiated adenocarcinoma (Gleason score equal to 6 or less) according to a postoperative morphological examination significantly increases a 5-year survival to BCR by 25.7 % (p = 0.047) compared to observation.

The paper provides comparative analysis of cancer specific survival among 202 patients treated with 3D-conformal radiotherapy or radical prostatectomy in N. N. Alexandrov National Cancer Centre of Belarus between 2005–2008. The proportional hazards regression model was used to estimate survival predictors.

Objective – assessing the predictive significance of clinical, histologic and biochemical factors for prediction of metastases in pelvic lymph nodes (MPLN), devising and validating of prognostic classification. Materials and methods. The study enrolled 1140 patients subjected to radical prostatectomy (RPE) with standard pelvic lymphadenectomy for prostate adenocarcinoma: 865 of them at the classification devising stage and 275 in the course of validation. Results. According to the findings of multivariate logistic regression analysis, PSA level, the tumor cT stage and Gleason score are independent predictors of MPLN detection after RPE (p 15, accounting for 3.5 % and 23.7 % respectively (р 15 and only in 1.3 % of those with a total estimate of prognostic factors < 10 (р < 0.0001).

Objective - assessing the predictive significance of clinical, histologic and biochemical factors for prediction of metastases in pelvic lymph nodes (MPLN), devising and validating of prognostic classification.Materials and methods. The study enrolled 1140 patients subjected to radical prostatectomy (RPE) with standard pelvic lymphadenectomy for prostate adenocarcinoma: 865 of them at the classification devising stage and 275 in the course of validation.Results. According to the findings of multivariate logistic regression analysis, PSA level, the tumor cT stage and Gleason score are independent predictors of MPLN detection after RPE (p < 0.05). The prognostic factors were stratified by score for assessing the detection of regional metastases after RPE, depending on the combination of predictors. In the group of patients with a score estimate of prognostic factors < 10, the MPLN detection rate was significantly lower than in the group of with a score estimate > 15, accounting for 3.5 % and 23.7 % respectively (p < 0.0001). In the course of validating the obtained findings in clinic, metastatic involvement of pelvic lymph nodes found in the result of RPE was diagnosed in 40.0 % of the patients with a score estimate > 15 and only in 1.3 % of those with a total estimate of prognostic factors < 10 (p < 0.0001).

The goal of the study was to evaluate cancer-specific survival in men with newly diagnosed prostate cancer after external beam radiotherapy. The long-term results of 178 patients treated with 3D-confirmal radiotherapy at N.N. Alexandrov National Cancer Centre of Belarus, Minsk, Belarus in 2005-2008 were analyzed. According to prostate-specific antigen level, clinical stage and Gleason sum patients were stratified into four groups of progression. 9-years cancerspecific survival in patients with low, intermediate, high and very high risk was 81,3±0,1%, 94,3±0,04%, 63,4±0,1% and 49,1±0,09%, respectively (р < 0,005).

Purpose. To evaluate influence of clinical, biochemical and histological factors to biochemical relapse free survival (BRFS) following salvage radiotherapy (RT) in men with biochemical recurrence after radical prostatectomy.Material and methods. 77 patients with newly diagnosed biochemical recurrence (BR) after RPE were included into retrospective study. All of them underwent local salvage RT. Сlinical variables (age, serum prostate-specific antigen [PSA] level and PSA kinetics, time RPE-BR, Gleason grade, stage after RPE and clinical findings) were evaluated using Cox proportional hazards regression analysis.Results. The median, 1- and 3-year BRFS were 19,9 months, 63,8 ± 6,5 % and 24,7 ± 8,5 % respectively. Significant variables in the multivariable model were age, PSA level before RT, prostatectomy T3b stage, PSA doubling time and positive digital rectal examination findings (p < 0,05). Several clinical parameters help predict the outcomes of men with PSA elevation after radical prostatectomy. These data may be useful in counseling men regarding the timing of administration of adjuvant therapies.